Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / AMPE - DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 17 2022 in Ampio Lawsuit - AMPE


AMPE - DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 17 2022 in Ampio Lawsuit - AMPE

New York, New York--(Newsfile Corp. - August 22, 2022) - Levi & Korsinsky, LLP notifies investors in Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) of a class action securities lawsuit.

The lawsuit on behalf of Ampio investors has been commenced in the the United States District Court for the District of Colorado. This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired Ampio common stock between December 29, 2020 and August 3, 2022, inclusive. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/ampio-lawsuit-submission-form?prid=31082&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Ampio Pharmaceuticals, Inc. NEWS - AMPE NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) defendants had inflated the Company's true ability to successfully file a Biologics License Application ("BLA") for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Ampio during the relevant timeframe, you have until October 17, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/ampio-lawsuit-submission-form?prid=31082&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/134532

Stock Information

Company Name: Ampio Pharmaceuticals Inc.
Stock Symbol: AMPE
Market: OTC
Website: ampiopharma.com

Menu

AMPE AMPE Quote AMPE Short AMPE News AMPE Articles AMPE Message Board
Get AMPE Alerts

News, Short Squeeze, Breakout and More Instantly...